By Denny Jacob
Sanofi said SAR446597, its treatment for geographic atrophy due to age-related macular degeneration, was granted fast-track designation by the Food and Drug Administration.
The French drugmaker said it plans to start a Phase 1/2 study to evaluate the safety, tolerability and efficacy of SAR446597.
Age-related macular degeneration is an acquired progressive degeneration of the retina, and geographic atrophy is an advanced form of dry AMD.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
July 16, 2025 06:17 ET (10:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.